Trial Profile
Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion With Water.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ramosetron (Primary)
- Indications Irritable bowel syndrome; Nausea and vomiting
- Focus Pharmacokinetics
- 11 Oct 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2011 New trial record